Therapeutic targeting of FLT3 and associated drug resistance in acute myeloid leukemia
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1756-8722
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Therapeutic targeting of FLT3 and associated drug resistance in acute myeloid leukemia ; volume:13 ; number:1 ; day:19 ; month:11 ; year:2020 ; pages:1-13 ; date:12.2020
Journal of hematology & oncology ; 13, Heft 1 (19.11.2020), 1-13, 12.2020
- Creator
-
Gebru, Melat T.
Wang, Hong-Gang
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s13045-020-00992-1
- URN
-
urn:nbn:de:101:1-2020123019353219422824
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:33 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Gebru, Melat T.
- Wang, Hong-Gang
- SpringerLink (Online service)
Other Objects (12)
FLT3 inhibitors in acute myeloid leukemia
Chronic myeloid leukemia stem cells: targeting therapeutic implications
Author Correction: SF3B1 as therapeutic target in FLT3/ITD positive acute myeloid leukemia
RSK1 dependency in FLT3-ITD acute myeloid leukemia
Chimeric antigen receptor (CAR)-modified T cells targeting FLT3 in acute myeloid leukemia (AML)
Targeting FLT3-TAZ signaling to suppress drug resistance in blast phase chronic myeloid leukemia
ULK1 inhibition as a targeted therapeutic strategy for FLT3-ITD-mutated acute myeloid leukemia
Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia
Targeting FLT3 in acute myeloid leukemia using ligand-based chimeric antigen receptor-engineered T cells
Indole-based FLT3 inhibitors and related scaffolds as potential therapeutic agents for acute myeloid leukemia
Distinct Metabolic features differentiating FLT3-ITD AML from FLT3-WT childhood Acute Myeloid Leukemia
Autophagy activation mediates resistance to FLT3 inhibitors in acute myeloid leukemia with FLT3-ITD mutation
FLT3 inhibitors in acute myeloid leukemia
Chronic myeloid leukemia stem cells: targeting therapeutic implications
Author Correction: SF3B1 as therapeutic target in FLT3/ITD positive acute myeloid leukemia
RSK1 dependency in FLT3-ITD acute myeloid leukemia
Chimeric antigen receptor (CAR)-modified T cells targeting FLT3 in acute myeloid leukemia (AML)
Targeting FLT3-TAZ signaling to suppress drug resistance in blast phase chronic myeloid leukemia
ULK1 inhibition as a targeted therapeutic strategy for FLT3-ITD-mutated acute myeloid leukemia
Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia
Targeting FLT3 in acute myeloid leukemia using ligand-based chimeric antigen receptor-engineered T cells
Indole-based FLT3 inhibitors and related scaffolds as potential therapeutic agents for acute myeloid leukemia
Distinct Metabolic features differentiating FLT3-ITD AML from FLT3-WT childhood Acute Myeloid Leukemia
Autophagy activation mediates resistance to FLT3 inhibitors in acute myeloid leukemia with FLT3-ITD mutation
FLT3 inhibitors in acute myeloid leukemia
Chronic myeloid leukemia stem cells: targeting therapeutic implications
Author Correction: SF3B1 as therapeutic target in FLT3/ITD positive acute myeloid leukemia
RSK1 dependency in FLT3-ITD acute myeloid leukemia
Chimeric antigen receptor (CAR)-modified T cells targeting FLT3 in acute myeloid leukemia (AML)
Targeting FLT3-TAZ signaling to suppress drug resistance in blast phase chronic myeloid leukemia
ULK1 inhibition as a targeted therapeutic strategy for FLT3-ITD-mutated acute myeloid leukemia
Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia
Targeting FLT3 in acute myeloid leukemia using ligand-based chimeric antigen receptor-engineered T cells
Indole-based FLT3 inhibitors and related scaffolds as potential therapeutic agents for acute myeloid leukemia
Distinct Metabolic features differentiating FLT3-ITD AML from FLT3-WT childhood Acute Myeloid Leukemia